55215-57-1

Basic information

• Product Name: 3-Bromo-5-nitroaniline
• Synonyms: 3-Bromo-5-nitroaniline;3-BroMo-5-nitrobenzenaMine;3-Amino-5-bromonitrobenzene;3-Bromo-5-nitroaniline 96%;3-Bromo-5-nitroaniline96%;5-Bromo-3-nitroaniline
• CAS NO: 55215-57-1
• Molecular Formula: C₆H₅BrN₂O₂
• Molecular Weight: 217
• Mol File: 55215-57-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 346.6±22.0 °C(Predicted)
• Appearance: /
• Density: 1.812±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 1.22±0.10(Predicted)
• CAS DataBase Reference: 3-Bromo-5-nitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-nitroaniline(55215-57-1)
• EPA Substance Registry System: 3-Bromo-5-nitroaniline(55215-57-1)

Safety Data

• Hazardous Substances Data: 55215-57-1(Hazardous Substances Data)

Usage

General Description

3-Bromo-5-nitroaniline is a chemical compound with the molecular formula C6H5BrN2O2. It is a yellow solid and is commonly used as an intermediate in the synthesis of pharmaceuticals, dyes, and other organic compounds. 3-Bromo-5-nitroaniline is a halogenated nitroaniline, which are known to have potential mutagenic and carcinogenic properties. Therefore, it is important to handle 3-Bromo-5-nitroaniline with caution and use appropriate safety measures when working with this chemical. Additionally, it is important to dispose of the compound properly in order to prevent environmental contamination.

Upstream product

• 99-65-0 meta-dinitrobenzene 
• 96558-80-4 1,2-dibromo-3,5-dinitrobenzene 
• 18242-39-2 3,5-dinitrobromobenzene 

Downstream Products

• 1430729-05-7 5-(5-bromo-1H-benzo[d]imidazol-1-yl)-2',4'-difluoro-[1,1'-biphenyl]-3-amine 
• 1430725-29-3 N-(5-(5-(1H-1,2,4-triazol-1-yl)-1H-benzo[d]imidazol-1-yl)-2',4'-difluoro-[1,1'-biphenyl]-3-yl)propionamide 
• 1430729-04-6 5-(5-(1H-1,2,4-triazol-1-yl)-1H-benzo[d]imidazol-1-yl)-2',4'-difluoro-[1,1'-biphenyl]-3-amine 
• 1430725-25-9 N-(5-(5-(1H-1,2,4-triazol-1-yl)-1H-benzo[d]imidazol-1-yl)-2',4'-difluoro-[1,1'-biphenyl]-3-yl)acetamide 
• 1430729-03-5 N-(5-((2-amino-4-(1H-1,2,4-triazol-1-yl)phenyl)amino)-2',4'-difluoro-[1,1'-biphenyl]-3-yl)acetamide 
• 1430729-02-4 N-(2',4'-difluoro-5-((2-nitro-4-(1H-1,2,4-triazol-1-yl)phenyl)amino)-[1,1'-biphenyl]-3-yl)acetamide 
• 1430725-14-6 N-(2',4'-difluoro-5-(6-(1-(1-methylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)-3H-imidazo[4,5-b]pyridin-3-yl)-[1,1'-biphenyl]-3-yl)cyclopropanecarboxamide 
• 1430725-13-5 N-(2',4'-difluoro-5-(6-(1-(1-methylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)-3H-imidazo[4,5-19]pyridin-3-yl)-[1,1'-biphenyl]-3-yl)ethanesulfonamide 
• 1430728-91-8 2',4'-difluoro-5-(6-(1-(1-methylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)-3H-imidazo[4,5-b]pyridin-3-yl)-[1,1'-biphenyl]-3-amine 
• 1430725-12-4 N-(2',4'-difluoro-5-(6-(1-(1-methylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)-3H-imidazo[4,5-b]pyridin-3-yl)-[1,1'-biphenyl]-3-yl)acetamide 
• 1430728-90-7 N-(5-(6-ethynyl-3H-imidazo[4,5-b]pyridin-3-yl)-2',4'-difluoro-[1,1'-biphenyl]-3-yl)acetamide 
• 1430728-89-4 N-(2',4'-difluoro-5-(6-((trimethylsilyl)ethynyl)-3H-imidazo[4,5-b]pyridin-3-yl)-[1,1'-biphenyl]-3-yl)acetamide 
• 1430728-88-3 N-(2',4'-difluoro-5-(6-iodo-3H-imidazo[4,5-b]pyridin-3-yl)-[1,1'-biphenyl]-3-yl)acetamide 
• 1430725-08-8 N-(2',4'-difluoro-5-(6-(6-fluoropyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3-yl)-[1,1'-biphenyl]-3-yl)acetamide 

Relevant articles and documents

Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds

Targeting the protein-protein interaction (PPI) between nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) is a potential therapeutic strategy to control diseases involving oxidative stress. Here, six classes of known small-molecule Keap1-Nrf2 PPI inhibitors were dissected into 77 fragments in a fragment-based deconstruction reconstruction (FBDR) study and tested in four orthogonal assays. This gave 17 fragment hits of which six were shown by X-ray crystallography to bind in the Keap1 Kelch binding pocket. Two hits were merged into compound 8 with a 220-380-fold stronger affinity (Ki = 16 μM) relative to the parent fragments. Systematic optimization resulted in several novel analogues with Ki values of 0.04-0.5 μM, binding modes determined by X-ray crystallography, and enhanced microsomal stability. This demonstrates how FBDR can be used to find new fragment hits, elucidate important ligand-protein interactions, and identify new potent inhibitors of the Keap1-Nrf2 PPI.

Indole and quinoline derivatives and its preparation method and application

The invention provides an indoloquinoline derivative, a preparation method and application thereof in preparing antitumor drugs and antiviral drugs. The chemical structure of the indoloquinoline derivative is shown as a formula I. Experiments show that a partly-boric-acid-modified indoloquinoline derivative and a non-boric-acid-modified indoloquinoline derivative have strong inhibition effect on various tumor cell strains, thereby being capable of being used for preparation of the antitumor drugs, and have strong antiviral activity, thereby being capable of being used for preparation of the antiviral drugs.

PROTEIN KINASE INHIBITORS

A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.